Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide controlled-release - Cosmo Pharmaceuticals

Next Previous
Drug Profile

Budesonide controlled-release - Cosmo Pharmaceuticals

Alternative Names: Budesonide controlled release; Budesonide CR; Budesonide MMX®; budesonide multimatrix; Cortiment; Cortiment MMX; FE 999315; Uceris oral

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Ferring Pharmaceuticals; Salix Pharmaceuticals
  • Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis

Most Recent Events

  • 28 Jun 2023 Registered for Ulcerative colitis (In adolescents, In the elderly, In adults) in Japan (PO)
  • 28 Jun 2023 Ferring Pharmaceuticals announces intention to initiate first sales of budesonide controlled-release (Cortiment®) for Ulcerative colitis in Japan (PO) by the end of Q3 2023
  • 19 Aug 2022 Pharmaceuticals and Medical Devices Agency (PMDA) has accepted NDA application for review

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top